Eye-disease-focused Acelyrin will be absorbed into immune-mediated disease specialist Alumis as part of an all-stock merger. The resulting company will continue under the Alumis name at the ...

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...

Acelyrin has punted the autoimmune drug prospect izokibep back to Affibody, completing a retreat from its former lead candidate that began with the axing of development in two diseases in August.

Alumis (ALUM) shares plunged ~17% in the premarket on Friday after the immunology-focused biopharma agreed to merge with its California-based rival Acelyrin (NASDAQ:SLRN) in an all-stock transaction.

ACELYRIN, Inc., a Los Angeles area-based, late-stage clinical biopharma, with additional operations in the San Francisco Bay area, has announced it is acquiring privately held ValenzaBio – which ...

The South San Francisco company (Nasdaq: ALMS) also will gain a drug, called lonigutamab, for thyroid eye disease from merger partner Acelyrin Inc. (Nasdaq: SLRN), but it said Thursday it will ...

16:13 EST Acelyrin (SLRN) Inc trading halted, news pending Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment ...

Alumis Inc. and ACELYRIN, Inc. have announced a definitive merger agreement for an all-stock transaction, with stockholders of each company owning approximately 55% and 45% of the combined entity ...

Biopharmaceutical companies Alumis and ACELYRIN said Thursday they have agreed to a merger which will see the combined company operate under the Alumis name with the current Alumis executive team.

Alumis (ALMS) and Acelyrin (SLRN) announced a definitive merger agreement under which Alumis and Acelyrin will merge in an all-stock transaction. Alumis and Acelyrin had cash, cash equivalents and ...

Experts and advocates to provide important strategic input and clinical expertise as ACELYRIN completes its Phase 2 trial of lonigutamab in TED and prepares to initiate Phase 3 program in first ...